Stuart A Arbuckle
CIK 1557290 · EVP, COO · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
130 WAVERLY ST.
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RYTM | Director | 11,712 | $113.23 | $1.33M | $0 | 10 | 2026-06-25 |
| PRAX | Director | 2,537 | $339.79 | $862.0K | $0 | 2 | 2026-06-12 |
| ALNY | Director | 671 | $154.42 | $103.6K | $0 | 2 | 2026-05-22 |
| VRTX | EVP, COO | 63,508 | $536.30 | $34.06M | -$139.91M | 122 | 2025-07-02 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 0 | $31.23 | $0 | $0 | 11 | 2024-02-12 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 1,310 | — | — | $0 | 4 | 2017-01-05 |
Recent Filings · Page 5 of 16
159 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-04 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +3,417 | $13.1K | EDGAR |
| 2023-02-28 | VRTX | Mixed | −9,748 | -$2.81M | EDGAR |
| 2023-02-24 | VRTX | Sell (S) | −2,401 | -$706.7K | EDGAR |
| 2023-02-22 | VRTX | Mixed | −6,900 | -$2.02M | EDGAR |
| 2023-02-16 | VRTX | Sell (S) | −6,398 | -$1.91M | EDGAR |
| 2023-02-14 | VRTX | Mixed | −14,249 | -$4.24M | EDGAR |
| 2023-02-03 | VRTX | Grant (A) | +38,221 | $0 | EDGAR |
| 2022-12-08 | VRTX | Grant (A) | +12,753 | $0 | EDGAR |
| 2022-08-17 | VRTX | Mixed | −15,602 | -$5.72M | EDGAR |
| 2022-08-12 | VRTX | Mixed | −116 | -$44.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.